Rupture of vulnerable atherosclerotic plaques: microRNAs conducting the orchestra?

Trends in Cardiovascular Medicine
Vincent G HaverRené A Tio

Abstract

MicroRNAs (miRNAs) are tiny, endogenous nucleotides that bind to mRNA and induce translation repression within metazoan cells. Since their discovery in 1993 in Caenorhabditis elegans and the demonstration of miRNAs in Homo sapiens in 2000, research has been fruitful in deciphering the role of these nucleotides in development, tissue homeostasis, and pathologic processes. In humans, around 700 human miRNA nucleotides have been verified, which interfere with 30% of all genes. Recently, the role of miRNA in cardiovascular research gained attention and the involvement of miRNAs in several cardiovascular diseases has been identified. In this review, we focus on the role of miRNAs in atherosclerosis and in particular on the potential role of miRNAs in the development of vulnerable atherosclerotic plaques. The role of miRNA in the main characteristics of these plaques, inflammation, angiogenesis, and apoptosis will be discussed. Finally, the future perspectives and miRNA-based diagnostic and therapeutic potentials will be highlighted.

References

Oct 27, 2001·Circulation Research·G J Blake, P M Ridker
May 19, 2004·European Journal of Clinical Investigation·G PasterkampD P V De Kleijn
Sep 17, 2004·Nature·Victor Ambros
Nov 1, 2005·Nature·Jan KrützfeldtMarkus Stoffel
Feb 7, 2006·Cell Metabolism·Christine EsauBrett P Monia
Oct 10, 2006·Oncogene·M Jovanovic, M O Hengartner
May 15, 2007·Journal of Molecular and Cellular Cardiology·Mariko TatsuguchiDa-Zhi Wang
May 26, 2007·The American Journal of Pathology·Yunhui ChengChunxiang Zhang
Jun 2, 2007·Circulation Research·Angelika KuehbacherStefanie Dimmeler
Jun 19, 2007·Trends in Cardiovascular Medicine·Willem E HellingsGerard Pasterkamp
Sep 25, 2007·Biochemical and Biophysical Research Communications·Zhongxing LiangHyunsuk Shim
Oct 12, 2007·Pharmacology & Therapeutics·Ming Yang, Joerg Mattes
Dec 11, 2007·Trends in Pharmacological Sciences·Angelika KuehbacherStefanie Dimmeler
Dec 15, 2007·Proceedings of the National Academy of Sciences of the United States of America·Jami McLaughlinOwen N Witte
Jan 30, 2008·Proceedings of the National Academy of Sciences of the United States of America·Tamia A HarrisCharles J Lowenstein
Feb 5, 2008·Current Opinion in Pharmacology·Elizabeth Scalbert, Antoine Bril
Apr 18, 2008·The Journal of Biological Chemistry·Pasquale FasanaroFabio Martelli
May 13, 2008·Biochemical and Biophysical Research Communications·Kaichi YoshizakiKeikichi Takahashi
Jul 2, 2008·Molecular and Cellular Biology·Galina GabrielyAnna M Krichevsky
Sep 20, 2008·Biochemical and Biophysical Research Communications·Xi-Yong YuYangxin Li
Oct 25, 2008·Circulation Research·Eva van RooijEric N Olson
Jan 30, 2009·Journal of Cellular and Molecular Medicine·E Sonkoly, A Pivarcsi
Feb 6, 2009·Proceedings of the National Academy of Sciences of the United States of America·Maurizio CeppiPhilippe Pierre
Feb 28, 2009·Biochemical and Biophysical Research Communications·Zhi-Xin ShanXi-Yong Yu
Feb 28, 2009·Circulation Research·Yajaira Suárez, William C Sessa
Mar 27, 2009·Journal of Cellular and Molecular Medicine·Paras Kumar MishraSuresh C Tyagi
May 19, 2009·Current Opinion in Genetics & Development·Shusheng Wang, Eric N Olson
Jun 10, 2009·International Heart Journal·Yehua TangGaozhong Huang
Jun 13, 2009·Recent Patents on Cardiovascular Drug Discovery·Pasquale SilvestriPaolo Loschiavo
Jun 16, 2009·Cell·Scott ValastyanRobert A Weinberg
Jun 23, 2009·Biochemical and Biophysical Research Communications·Fusheng WuGuohong Li
Jul 3, 2009·Journal of Vascular Research·Chandan K SenSashwati Roy
Aug 20, 2009·The Journal of Clinical Investigation·Thomas BoettgerThomas Braun
Aug 22, 2009·Clinical Chemistry·Xu JiNaoharu Iwai
Aug 27, 2009·The Journal of Biological Chemistry·Shimin DongChunxiang Zhang
Sep 2, 2009·Proceedings of the National Academy of Sciences of the United States of America·Gang LiuEdward Abraham
Oct 15, 2009·The Journal of Biological Chemistry·Pasquale FasanaroFabio Martelli
Nov 10, 2009·Biochemical and Biophysical Research Communications·Jing AiBaofeng Yang
Dec 2, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yajaira SuárezJordan S Pober

❮ Previous
Next ❯

Citations

Oct 19, 2012·Biomarkers in Medicine·Anisha Banerjee, Karsta Luettich
Sep 16, 2010·Physiological Genomics·Cameron Rink, Savita Khanna
May 31, 2011·Frontiers in Bioscience (Landmark Edition)·Anthony VirtueXiao-Feng Yang
Aug 1, 2012·Current Atherosclerosis Reports·Katey J Rayner, Kathryn J Moore
Oct 15, 2013·Trends in Cardiovascular Medicine·Andreas Eisenreich, Ulrike Leppert
Oct 13, 2011·Scandinavian Journal of Immunology·Tereza TomankovaEva Kriegova
Dec 7, 2013·Journal of Biomedical Materials Research. Part B, Applied Biomaterials·Nelisa T Laçin, Guldem G Utkan
Jun 29, 2015·Atherosclerosis·Evangelos K EconomouDimitris Tousoulis
Mar 16, 2013·Journal of cardiology·Annalisa CaroliLuigi M Biasucci
Jul 3, 2015·Cardiology in Review·Nikolaos PapageorgiouDimitris Tousoulis
Jun 19, 2019·Proceedings of the Institution of Mechanical Engineers. Part H, Journal of Engineering in Medicine·Danny VogelRainer Bader
Aug 1, 2013·Physiological Reviews·Paul N Hopkins
Oct 17, 2019·Kardiologiia·N G KukavaO O Favorova
May 16, 2020·Antioxidants & Redox Signaling·Mohammed Rabiul HosenFelix Jansen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics (ASM)

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Cell Adhesion Molecules in AS

Cell adhesion molecules expressed on the vascular endothelium and circulating leukocytes in response to inflammatory stimuli are implicated in atherosclerosis. Here is the latest research.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

© 2021 Meta ULC. All rights reserved